WO2010080558A1 - Formes polymorphiques du (s)-3-aminométhyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2]oxaborol-1-ol - Google Patents

Formes polymorphiques du (s)-3-aminométhyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2]oxaborol-1-ol Download PDF

Info

Publication number
WO2010080558A1
WO2010080558A1 PCT/US2009/068609 US2009068609W WO2010080558A1 WO 2010080558 A1 WO2010080558 A1 WO 2010080558A1 US 2009068609 W US2009068609 W US 2009068609W WO 2010080558 A1 WO2010080558 A1 WO 2010080558A1
Authority
WO
WIPO (PCT)
Prior art keywords
species
aminomethyl
propoxy
oxaborol
hydroxy
Prior art date
Application number
PCT/US2009/068609
Other languages
English (en)
Inventor
Conrad Wheeler
Dan Todd
Pingyun Chen
Beth A. Norton
Original Assignee
Anacor Pharmaceuticals, Inc.
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA201190034A priority Critical patent/EA201190034A1/ru
Priority to EP09837955A priority patent/EP2378886A4/fr
Priority to JP2011542458A priority patent/JP2012512262A/ja
Priority to CN2009801506662A priority patent/CN102256494A/zh
Priority to AU2009335744A priority patent/AU2009335744A1/en
Priority to MX2011006334A priority patent/MX2011006334A/es
Application filed by Anacor Pharmaceuticals, Inc., Glaxosmithkline Llc filed Critical Anacor Pharmaceuticals, Inc.
Priority to CA2744231A priority patent/CA2744231A1/fr
Priority to MA34028A priority patent/MA32977B1/fr
Priority to SG2011041894A priority patent/SG172040A1/en
Priority to BRPI0922566A priority patent/BRPI0922566A2/pt
Publication of WO2010080558A1 publication Critical patent/WO2010080558A1/fr
Priority to IL213060A priority patent/IL213060A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Definitions

  • This invention provides, among other things, crystalline polymorphs of the hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H- benzo[c] [ 1 ,2]oxaborol- 1 -ol.
  • pharmaceutically acceptable carrier or “pharmaceutically acceptable vehicle” refers to any formulation or carrier medium that provides the appropriate delivery of an effective amount of an active agent as defined herein, does not interfere with the effectiveness of the biological activity of the active agent, and that is sufficiently non-toxic to the host or patient.
  • Representative carriers include water, oils, both vegetable and mineral, cream bases, lotion bases, ointment bases and the like. These bases include suspending agents, thickeners, penetration enhancers, and the like. Their formulation is well known to those in the art of cosmetics and topical pharmaceuticals. Additional information concerning carriers can be found in Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005) which is incorporated herein by reference.
  • the invention provides polymorph form HCIl having, upon XRPD analysis, any 10, any 9, any 8, any 7, any 6, any 5, any 4, any 3, any 2 or any 1 of the peaks shown in Figures IA and IB, ⁇ 2°2 ⁇ , ⁇ 1.7°2 ⁇ , ⁇ 1.5°2 ⁇ , ⁇ 1.2°2 ⁇ , ⁇ 1.0°2 ⁇ , ⁇ 0.9°2 ⁇ , ⁇ 0.8°2 ⁇ , ⁇ 0.7°2 ⁇ , ⁇ 0.6°2 ⁇ , ⁇ 0.5°2 ⁇ , ⁇ 0.4°2 ⁇ , ⁇ 0.3°2 ⁇ , ⁇ 0.2°2 ⁇ , or ⁇ 0.T2 ⁇ .
  • the invention provides polymorph form HC13 having, upon XRPD analysis, any 10, any 9, any 8, any 7, any 6, any 5, any 4, any 3, any 2 or any 1 of the peaks shown in Figures 3A and 3B, ⁇ 2°2 ⁇ , ⁇ 1.7°2 ⁇ , ⁇ 1.5°2 ⁇ , ⁇ 1.2°2 ⁇ , ⁇ 1.0°2 ⁇ , ⁇ 0.9°2 ⁇ , ⁇ 0.8°2 ⁇ , ⁇ 0.7°2 ⁇ , ⁇ 0.6°2 ⁇ , ⁇ 0.5°2 ⁇ , ⁇ 0.4°2 ⁇ , ⁇ 0.3°2 ⁇ , ⁇ 0.2°2 ⁇ , or ⁇ 0.1°2 ⁇ .
  • polymorph form HC14 The XRPD pattern for another polymorph of (S)-3-aminomethyl-7-(3- hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol-HCl, referred to as polymorph form HC14, and its 2-theta (2 ⁇ ) values are shown in Figures 4A and 4B. Additional studies, including a single crystal form screen, verify that HC14 is the most stable polymorph of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c] [ 1 ,2]oxaborol- 1-ol.HCl. In an exemplary embodiment, the invention provides polymorph form
  • HC14 having, upon XRPD analysis, any 10, any 9, any 8, any 7, any 6, any 5, any 4, any 3, any 2 or any 1 of the peaks shown in Figures IA and IB, ⁇ 2°2 ⁇ , ⁇ 1.7°2 ⁇ , ⁇ 1.5°2 ⁇ , ⁇ 1.2°2 ⁇ , ⁇ 1.0°2 ⁇ , ⁇ 0.9°2 ⁇ , ⁇ 0.8°2 ⁇ , ⁇ 0.7°2 ⁇ , ⁇ 0.6°2 ⁇ , ⁇ 0.5°2 ⁇ , ⁇ 0.4°2 ⁇ , ⁇ 0.3°2 ⁇ , ⁇ 0.2°2 ⁇ , or ⁇ 0.1 °2 ⁇ .
  • the invention provides polymorph form HC14 having, upon XRPD analysis, any 10 of the peaks shown in Figures 4A and 4B, ⁇ 2°2 ⁇ , ⁇ 1.7°2 ⁇ , ⁇ 1.5°2 ⁇ , ⁇ 1.2°2 ⁇ , ⁇ 1.0°2 ⁇ , ⁇ 0.9°2 ⁇ , ⁇ 0.8°2 ⁇ , ⁇ 0.7°2 ⁇ , ⁇ 0.6°2 ⁇ , ⁇ 0.5°2 ⁇ , ⁇ 0.4°2 ⁇ , ⁇ 0.3°2 ⁇ , ⁇ 0.2°2 ⁇ , or ⁇ 0.1°2 ⁇ .
  • the invention provides polymorph form HC14 having, upon X-ray crystallographic analysis, a P2i2i2i space group.
  • the invention provides a polymorph having, upon Raman spectroscopic analysis, any 15, any 14, any 13, any 12, any 10, any 11, any 9, any 8, any 7, any 6, any 5, any 4, any 3, any 2 or any 1 of the peaks having substantially the following wavenumbers (cm 1 ) selected from the group: 3076.4, 3054.6, 2987.4, 2975.5, 2954.2, 2928.0, 2909.8, 2896.0, 1578.6, 1298.2, 1291.6, 1263.0, 1226.8, 1068.9, 694.9, ⁇ 50 wavenumbers, ⁇ 45 wavenumbers, ⁇ 40 wavenumbers, ⁇ 35 wavenumbers, ⁇ 30 wavenumbers, ⁇ 25 wavenumbers, ⁇ 20 wavenumbers, ⁇ 15 wavenumbers, ⁇ 10 wavenumbers, or ⁇ 5 wavenumbers.
  • wavenumbers selected from the group: 3076.4, 3054.6, 2987.4, 2975.5, 2954.2, 2928.0, 2909.8, 289
  • the invention provides a polymorph having an XRPD pattern substantially as depicted in any of Figures 4A, 7 or 8 A.
  • the invention provides a polymorph having substantially the peaks listed in Figure 8B, and the corresponding d-spacing values.
  • a polymorph having XRPD peaks selected from any 15, any 14, any 13, any 12, any 11, any 10, any 9, any 8, any 7, any 6, any 5, any 3, and 2 or any 1 of the peaks having substantially the 2 ⁇ values selected from the group: 12.1, 14.2, 18.2, 19.2, 20.1, 21.0, 21.9, 22.7, 24.3, 26.6, 27.6, 30.9, 31.5, 34.7, or 39.5.
  • the polymorph is produced by evaporation and/or recrystallization from a solution with a concentration of (S)-3-aminomethyl-7- (3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol ⁇ Cl of about 11 mg/mL or greater.
  • concentration of (S)-3-aminomethyl-7-(3- hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol-HCl is about 15 mg/mL or greater.
  • the concentration of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c] [ 1 ,2]oxaborol-l -ol-HCl is from about 15 mg/mL to about 500 mg/mL.
  • the solution comprises an alcohol.
  • the solution comprises methanol.
  • the solution comprises ethanol.
  • the solution comprises an aliphatic compound.
  • the solution comprises pentane.
  • the present invention relates to polymorph form HC14 of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H- benzo[c][l,2]oxaborol-l-ol-HCl.
  • the polymorph form HC14 of (S)-3-aminomethyl-7- (3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol ⁇ Cl exhibits increased stability when compared to other polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)- 3H-benzo[c][l,2]oxaborol-l-ol ⁇ Cl.
  • the stability is physical stability.
  • the stability is chemical stability.
  • the present invention relates to a process for producing a purified version of the HC14 polymorph of (S)-3-aminomethyl-7-(3- hydroxy-propoxy)-3H-benzo[c] [ 1 ,2]oxaborol- 1 -ol-HCl.
  • the invention provides a method of treating a disease in an animal suffering from the disease, comprising: administering to the animal a therapeutically effective amount of a polymorph described herein, thereby treating the disease.
  • the disease is associated with a bacteria.
  • the bacteria is a Gram negative bacteria.
  • the Gram negative bacteria is selected from the group consisting of
  • the disease is selected from the group consisting of meningitis, gonorrhea, otitis, otitis externa, folliculitis, diarrhea, urinary tract infections, sepsis, HAP, bacteremia, endocarditis, gastroenteritis, Typhoid fever, supsis, endocarditis, sinusitis, bubonic plague, enteric fever, hospital-acquired infection, skin and skin-structure infection, pneumonia, cholera, chronic gastritis, osteomylitis, burn-wound infections, corneal infections, periodontal disease, aspriation pneumonia, piglottitis, septic arthritis, chancroid, vaginitis, whooping cough, pontiac fever, tularemia, brucellosis, syphilis, Lyme disease, chlamydia, Rocky Mountain spotted fever, typhus, tracheobronchitis, walking pneumonia, urethritis, pyel
  • the disease is pneumonia.
  • the polymorph is polymorph form HC14 of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c] [ 1 ,2]oxaborol- 1 -ol-HCl.
  • the polymorph has substantially similar X-ray crystallographic values to those described herein.
  • the polymorph has substantially similar Raman spectroscopic values to those described herein.
  • the polymorph has substantially similar X-ray powder diffraction patterns to those described herein.
  • a further aspect of the present invention relates to a pharmaceutical composition which comprises: a) polymorph of the hydrochloride salt of (S)-3- aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol and b) at least one excipient or carrier.
  • the polymorph is polymorph form HCW of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol- 1-ol ⁇ Cl.
  • the polymorph has substantially similar X- ray crystallographic values to those described herein.
  • the polymorph has substantially similar Raman spectroscopic values to those described herein. In an exemplary embodiment, the polymorph has substantially similar X-ray powder diffraction patterns to those described herein.
  • This pharmaceutical composition is useful for treating disease involving bacteria.
  • the polymorph is described herein.
  • the bacteria is described herein.
  • the disease is described herein.
  • the instant invention relates to the use of the HC14 polymorph of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c] [ 1 ,2]oxaborol-l -ol-HCl for the preparation of a medicament for the treatment of a disease described herein.
  • the disease is associated with a Gram negative bacteria.
  • Particular preferred according to the invention is the use of the HC14 polymorph of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c] [ 1 ,2]oxaborol- 1 -ol-HCl for the preparation of a medicament for the treatment of a disease selected herein.
  • compositions comprising as an active ingredient a polymorph of (S)- 3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol ⁇ Cl in addition with at least one pharmaceutical carrier.
  • the polymorph of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H- benzo[c][l,2]oxaborol-l-ol-HCl may be incorporated into the conventional pharmaceutical preparation in solid, liquid, ointment, cream, suspension or spray form.
  • compositions may, for example, be presented in a form suitable for oral, rectal, parenteral administration or for nasal inhalation: preferred forms include for example, capsules, tablets, coated tablets, ampoules, suppositories and nasal spray.
  • the active ingredient may be incorporated in excipients or carriers conventionally used in pharmaceutical compositions such as, for example, talc, arabic gum, lactose, gelatine, magnesium stearate, corn starch, aqueous or non aqueous vehicles, polyvynil pyrrolidone, semisynthetic glycerides of fatty acids, benzalconium chloride, sodium phosphate, EDTA, polysorbate 80.
  • Another particular embodiment provides a polymorph comprising any 4 peaks as depicted in XRPD pattern 1. Still another exemplary embodiment provides a polymorph comprising any 7 peaks as depicted in XRPD pattern 1. A more particular embodiment provides a polymorph comprising any 10 peaks as depicted in XRPD pattern 1. Still another more particular embodiment provides a polymorph comprising all peaks as depicted in XRPD pattern 1.
  • Another exemplary embodiment provides a polymorph polymorph of a hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H- benzo[c][l,2]oxaborol-l-ol wherein the polymorph is characterized by having any of the 2 ⁇ values listed in Table 1, ⁇ 2°2 ⁇ , ⁇ 1.7°2 ⁇ , ⁇ 1.5°2 ⁇ , ⁇ 1.2°2 ⁇ , ⁇ 1.0°2 ⁇ , ⁇ 0.9°2 ⁇ , ⁇ 0.8°2 ⁇ , ⁇ 0.7°2 ⁇ , ⁇ 0.6°2 ⁇ , ⁇ 0.5°2 ⁇ , ⁇ 0.4°2 ⁇ , ⁇ 0.3°2 ⁇ , ⁇ 0.2°2 ⁇ , or ⁇ 0.1°2 ⁇ :
  • Another exemplary embodiment provides a polymorph polymorph of a hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H- benzo[c][l,2]oxaborol-l-ol wherein the polymorph is characterized by having any of the 2 ⁇ values listed in Table 2, ⁇ 2°2 ⁇ , ⁇ 1.7°2 ⁇ , ⁇ 1.5°2 ⁇ , ⁇ 1.2°2 ⁇ , ⁇ 1.0°2 ⁇ , ⁇ 0.9°2 ⁇ , ⁇ 0.8°2 ⁇ , ⁇ 0.7°2 ⁇ , ⁇ 0.6°2 ⁇ , ⁇ 0.5°2 ⁇ , ⁇ 0.4°2 ⁇ , ⁇ 0.3°2 ⁇ , ⁇ 0.2°2 ⁇ , or ⁇ 0.1°2 ⁇ :
  • Still another exemplary embodiment provides a polymorph of a hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H- benzo[c][l,2]oxaborol-l-ol having, upon X-ray crystallographic analysis, crystal parameters of substantially the following values:
  • Another exemplary embodiment provides a polymorph of a hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol, characterized by having any of the peaks of Raman spectrum (1):
  • Yet another exemplary embodiment provides a pharmaceutical composition comprising a polymorph as described and at least one excipient or carrier.
  • Another exemplary embodiment provides a method for treating a disease in an animal suffering from said disease, comprising administering to the animal a therapeutically effective amount of a polymorph as described herein, wherein said disease is associated with a bacteria.
  • Yet another exemplary embodiment provides a method for treating a disease in an animal suffering from a disease as described wherein the bacteria is a Gram negative bacteria.
  • the bacteria is selected from the group consisting of Neisseria species, Escherichia species, Shigella species, Salmonella species, Yersinia species, Klebsiella species, Proteus species, Enterobacter species, Serratia species, Vibrio species, Campylobacter species, Helicobacter species, Pseudomonas species, Bacteroides species, Haemophilus species, Bordetella species, Legionella species, Francisella species, Brucella species, Pasteurella species, Gardnerella species, Spirochetes species, Chlamydia species and Rickettsiae species.
  • Still another exemplary embodiment provides a method for treating a disease in an animal suffering from said disease as described, wherein the disease is selected from the group consisting of meningitis, gonorrhea, otitis, otitis externa, folliculitis, diarrhea, urinary tract infections, sepsis, HAP, bacteremia, endocarditis, gastroenteritis, Typhoid fever, supsis, endocarditis, sinusitis, bubonic plague, enteric fever, hospital-acquired infection, skin and skin-structure infection, pneumonia, cholera, chronic gastritis, osteomylitis, burn-wound infections, corneal infections, periodontal disease, aspriation pneumonia, piglottitis, septic arthritis, chancroid, vaginitis, whooping cough, pontiac fever, tularemia, brucellosis, syphilis, Lyme disease, chlamydia, Rocky Mountain spotted fever, typhus
  • Yet another exemplary embodiment provides a method for treating a disease in an animal suffering from said disease as described, wherein the disease is pneumonia.
  • Another exemplary embodiment provides crystalline (S)-3-aminomethyl- 7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol ⁇ Cl, form HC14.
  • Another exemplary embodiment provides crystalline (S)-3-aminomethyl-7-(3-hydroxy- propoxy)-3H-benzo[c][l,2]oxaborol-l-ol-HCl, form HC13.
  • Still another exemplary embodiment provides a method of preparing crystalline (S)-3-aminomethyl-7-(3 -hydroxy - propoxy)-3H-benzo[c][l,2]oxaborol-l-ol-HCl, form HCW, HC13, HC12, HCIl as described above.
  • the invention is a crystalline polymorph characterized by having essentially any of the °2 ⁇ values listed in Table 1 ⁇ 0.2°2 ⁇ :
  • the invention is a crystalline polymorph of a hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H- benzo[c][l,2]oxaborol-l-ol, characterized by having essentially any of the peaks of XRPD pattern 1 ⁇ 0.2°2 ⁇ Coun
  • the invention is a crystalline polymorph of a hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H- benzo[c][l,2]oxaborol-l-ol having, upon X-ray crystallographic analysis, crystal parameters of substantially the following values:
  • the invention is a crystalline polymorph of a hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H- benzo[c][l,2]oxaborol-l-ol, characterized by having any of the peaks, ⁇ 50 wavenumbers (cm 1 ) of Raman spectrum (1):
  • the crystalline polymorph has a multiplet of peaks between about 2800 and about 3200 cm “1 , ⁇ 50 wavenumbers, and another multiplet of peaks between about 1600 and about 600 cm “1 , ⁇ 50 wavenumbers, and an essential absence of peaks between about 1800 and about 2200 cm “1 , ⁇ 50 wavenumbers.
  • the crystalline polymorph has a multiplet of peaks between about 2800 and about 3200 cm "1 , ⁇ 50 wavenumbers, ⁇ 45 wavenumbers, ⁇ 40 wavenumbers, ⁇ 35 wavenumbers, ⁇ 30 wavenumbers, ⁇ 25 wavenumbers, ⁇ 20 wavenumbers, ⁇ 15 wavenumbers, ⁇ 10 wavenumbers, and ⁇ 5 wavenumbers.
  • the crystalline polymorph has multiplet of peaks between about 1600 and about 600 cm "1 , ⁇ 50 wavenumbers, ⁇ 45 wavenumbers, ⁇ 40 wavenumbers, ⁇ 35 wavenumbers, ⁇ 30 wavenumbers, ⁇ 25 wavenumbers, ⁇ 20 wavenumbers, ⁇ 15 wavenumbers, ⁇ 10 wavenumbers, and ⁇ 5 wavenumbers.
  • the crystalline polymorph has an essential absence of peaks between about 1800 and about 2200 cm "1 , ⁇ 50 wavenumbers, ⁇ 45 wavenumbers, ⁇ 40 wavenumbers, ⁇ 35 wavenumbers, ⁇ 30 wavenumbers, ⁇ 25 wavenumbers, ⁇ 20 wavenumbers, ⁇ 15 wavenumbers, ⁇ 10 wavenumbers, and ⁇ 5 wavenumbers.
  • the invention provides a pharmaceutical composition comprising: a) the crystalline polymorph according to any of the above paragraphs; and b) at least one excipient or carrier.
  • the invention provides a method for treating a disease in an animal suffering from the disease, comprising: administering to the animal a therapeutically effective amount of the crystalline polymorph of any of the above paragraphs, wherein said disease is associated with a bacteria.
  • the bacteria is a Gram negative bacteria.
  • the bacteria is selected from the group consisting of Neisseria species, Escherichia species, Shigella species, Salmonella species, Yersinia species, Klebsiella species, Proteus species, Enterobacter species, Serratia species, Vibrio species, Campylobacter species, Helicobacter species, Pseudomonas species, Bacteroides species, Haemophilus species, Bordetella species, Legionella species, Francisella species, Brucella species, Pasteurella species, Gardnerella species, Spirochetes species, Chlamydia species and Rickettsiae species.
  • the disease is selected from the group consisting of meningitis, gonorrhea, otitis, otitis externa, folliculitis, diarrhea, urinary tract infections, sepsis, HAP, bacteremia, endocarditis, gastroenteritis, Typhoid fever, supsis, endocarditis, sinusitis, bubonic plague, enteric fever, hospital-acquired infection, skin and skin-structure infection, pneumonia, cholera, chronic gastritis, osteomylitis, burn-wound infections, corneal infections, periodontal disease, aspriation pneumonia, piglottitis, septic arthritis, chancroid, vaginitis, whooping cough, pontiac fever, tularemia, brucellosis, syphilis, Lyme disease, chlamydia, Rocky Mountain spotted fever, typhus, tracheobronchitis
  • the invention is crystalline (S)-3- aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol-HCl, form HC14.
  • the invention is crystalline (S)-3- aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol-HCl, form HC13.
  • the invention is crystalline (S)-3- aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol-HCl, form HC12.
  • the invention is crystalline (S)-3- aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c] [1 ,2]oxaborol- 1 -ol-HCl, form HCIl.
  • the invention is a method of preparing crystalline (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l- ol-HCl, form HC14, HC13, HC12, HCIl as described herein.
  • the invention is a method of preparing crystalline (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l- ol-HCl, form HC14, HC13, HC12, HCIl as described in any of the above paragraphs.
  • the column temperature was at rt with the flow rate of 1.0 mL/min.
  • the Diode Array Detector was scanned from 200-400 nm. For high purity samples requiring baseline subtraction, a linear gradient was applied, starting at 99% A (A: 0.1% H 3 PO 4 in water) and ending at 90% B (B: MeCN) over 15 min. The column was then re- equilibrated over 3 min to 99% A with a total run time of 23 min. The column temperature was at rt with the flow rate of 1.0 mL/min.
  • the Diode Array Detector was scanned from 200-400 nm. A blank MeOH sample was run immediately prior to the sample of which purity was to be determined: this was then subtracted to obtain the baseline subtracted chromatogram.
  • TLC Thin layer chromatography
  • Alugram ® Silica gel 60 F 254
  • UV was typically used to visualize the spots. Additional visualization methods were also employed in some cases.
  • the TLC plate was developed with iodine (generated by adding approximately 1 g of I 2 to 10 g silica gel and thoroughly mixing), vanillin (generated by dissolving about 1 g vanillin in 100 mL 10% H 2 SO 4 ), potassium permanganate (generated by dissolving 1.5 g KMnO 4 and 10 g K 2 CO 3 in 1.25 mL NaOH and 200 mL H 2 O), ninhydrin (available commercially from Aldrich), or Magic Stain (generated by thoroughly mixing 25 g (NH 4 ) 6 Mo 7 O 24 «4H 2 O, 5 g (NH 4 ) 2 Ce(IV)(NO 3 ) 6 in 450 mL H 2 O and 50 mL cone H 2 SO 4 )
  • Flash chromatography was preformed using typically 40-63 ⁇ m (230-400 mesh) silica gel from Silicycle following analogous techniques to those disclosed by Still et al.
  • Typical solvents used for flash chromatography or thin layer chromatography (TLC) were mixtures of CHCl 3 /MeOH, CH 2 Cl 2 MeOH, EtOAc/MeOH and hexane/EtOAc.
  • Reverse phase flash chromatography were performed on a Biotage ® using a Biotage C 18 cartridges and a H 2 O/MeOH gradient (typically eluting from 5% MeOH/H 2 O to 90% MeOH/H 2 O).
  • Preparative chromatography was performed on either a Waters Prep LC 4000 System using a Waters 2487 Diode Array or on a Waters LC Module 1 plus.
  • the column used were either a Waters x Terra Prep C 18 , 5 ⁇ m, 30 x 100 mm, Phenomenex Luna C 18 , 5 ⁇ m, 21.6 x 250 mm, or a Phenomenex Gemini C 18 , 5 ⁇ m, 100 x 30 mm.
  • Narrow gradients with MeCNZH 2 O water containing either 0.1% TFA, 0.1% AcOH, 0.1% HCO 2 H or 0.1% NH 4 OAc) were used to elute the compound at a flow rate of approximately 20 mL/min and a total run time between 20-30 min.
  • the reaction mixture was allowed to cool to room temperature (T ⁇ 25°C) and 15O g of Celite was added. The mixture was stirred for approximately 1 hour. The reaction mixture was filtered on a ceramic funnel with filter paper. The solid was washed with 3 x IL THF (until the filtrate was clear and the solid was white or off white). The solid was mostly KOAc and other insoluble salt by-products formed during the reaction. The desired product was dissolved in the filtrate. [0108] Using a Rotavap (bath temperature ⁇ 45°C), the solvent was stripped from the filtrate until a thick dark oil remained.
  • ReactorR-21 25 gal Reactor
  • ReactorR-21 331 g of 5, 144 g 20% Pd(OH) 2 /C, and 2OL of 2M NH 3 /methanol solution.
  • the volume of solvent for this reaction was based on the minimum stirring volume in the 25 gallon reactor.
  • the reactor was pressurized and purged with nitrogen three times.
  • the mixture was hydrogenated at 35-40 psi H 2 while circulating cold water through reactor jacket.
  • the reaction was complete by HPLC analysis after approximately 17 hours.
  • the reaction mixture was filtered through a cartridge (2 micron) into R-20 (second 25 gal glass lined reactor).
  • R-21 was then rinsed with approximately 5 L methanol and the rinse transferred through a filter cartridge to R-20.
  • the mixture was stripped mixture to an oil under vacuum (temperature ⁇ 40°C).
  • the residue was titrated with 3x10 L MTBE and stripped to an oil each time to remove excess NH 3 .
  • the oil was redissolved in -0.65M HCl/methanol solution.
  • the solution was transferred back to R-21 and the reactor was charged with 72 g 20% Pd(OH) 2 /C catalyst.
  • the reactor was purged three times with nitrogen.
  • the mixture was hydrogenated at 35-40 psi H 2 while circulating cold water through the reactor jacket.
  • the reaction was complete by HPLC analysis after approximately 3 hours.
  • the reaction mixture was filtered through a cartridge (2 micron) into R-20.
  • R-21 was rinsed with approximately 5 L methanol and the rinsed methanol was sent through a filter cartridge into R-20.
  • Samples were submitted for % Pd at various points throughout the process to pinpoint the effectiveness of the Pd removal and to make sure the batch would pass the %Pd specification.
  • the filtered solution was treated with 25 g of thiol silica and stirred at room temperature overnight. The mixture was filtered through a 2 micron filter cartridge into 2OL glass carboys. [0116] The filtered solution was stripped to an oil using a Rotavap (temperature ⁇ 40°C). Crystals started forming while stripping. Methanol (300 rnL) was added to the oil and the mixture stirred at room temperature overnight. A thick slurry of crystallized product was obtained.
  • the solution was stripped to a thick slurry via Rotavap (temperature ⁇ 40°C).
  • the stripped residue was titrated with 3x400 mL Ethanol SDA-3A to remove excess NH 3 .
  • the solution was stripped to a thick slurry after each addition of ethanol.
  • EtOH SDA-3A (1200ml) was added to the resulting slurry and stirred for approximately 30 minutes. An additional 1500 mL methanol was added to the mixture. The solution stirred for 30 minutes.
  • the mixture was filtered through GF paper to remove insoluble salts and then washed with 3x300mL MeOH. Salts were collected and dried for mass balance (approximately 64.2 g).
  • the clear filtrate was stripped to a solid/slurry Rotavap (temperature ⁇ 40°C).
  • the stripped 7 freebase was dissolved in 1850 mL methanol. A clear solution was obtained.
  • the aqueous layer was placed in the Freeze Dryer (FD-I Virtis Freezemobile 25ES). The initial temperature was 19°C. After approximately 2 hours, the product was frozen and temperature was approximately -45°C. The shelf temperature was increased to - 20 0 C. After approximately 3 days, the shelf temperature was raised to 0 0 C. After 4 hours, the shelf temperature was raised to 20 0 C. After an additional 4.5 hours, the shelf temperature was increased to 30 0 C. After approximately 16.5 hours at the shelf temperature of 30 0 C, the product was taken out of the freeze dryer and packaged in Nalgene bottles. Yield of 11: 28.5 g.
  • the solution was then warmed up (10 °C/min) to 60 0 C and kept at 60 0 C for 1 hour. Afterwards the solution was cooled down with 20 °C/h to 5 0 C and then aged for 48 h at 5 0 C. The solvent was then evaporated under vacuum (17.5 hours at 500 mbar followed by 72 hours at 200 mbar) at room temperature, until dryness.
  • the HC12 form was also obtained by re-crystallization from ethanol/water (95/5, v/v) of the HC12 form.
  • an amount of approximately 4 mg of HC12 salt form was dissolved in approximately 1 mL of ethanol/water (95/5, v/v).
  • the solution was then warmed up (10 °C/min) to 60 0 C and kept at 60 0 C for 1 hour. Afterwards the solution was cooled down with 20 °C/h to 5 0 C and then aged for 48 h at 5 0 C.
  • the solvent was then evaporated under vacuum (17.5 hours at 500 mbar followed by 72 hours at 200 mbar) at room temperature, until dryness.
  • the HC14 form was also obtained by re-crystallization from pentane of the HC14 form. In this process an amount of approximately 59 mg of HC14 salt form was dissolved in approximately 2.5 mL of pentane. The solution was then warmed up (10 °C/min) to 60 0 C and kept at 60 0 C for 1 hour. Afterwards the solution was cooled down with 20 °C/h to 5 0 C and then aged for 48 h at 5 0 C. The solvent was then evaporated under vacuum (66.5 hours at 200 mbar followed by 7.3 hours at 1 mbar) at room temperature, until dryness.
  • the HCIl polymorph which was a hard bulky material, was placed in a closed Amber bottle and stored under ambient conditions. Four months later, the bottle was opened, and the hard bulky material was now a free flowing powder. An XRPD was taken of this free flowing powder. The similarities in the XRPD of the free flowing powder with a reference XRPD of the HC14 form indicates that the free flowing powder is in the HC14 form. The result indicates that the initial HCIl form had converted into the HC14 form during storage. This result indicates that HC14 is a more stable polymorph than HCIl .
  • XRPD data comparing the free base form, polymorph form HCIl and polymorph form HC14 is provided in Figure 5.
  • the solvents included water, methanol, 1-propanol, nitromethane, acetonitrile, dimethylsulfoxide, acetone, 2- butanone, dichloromethane, methyl acetate, 4-methyl-2-chloroform, ethyl acetate, chlorobenzene, tetrahydrofuran, 1,4-dioxane, isopropyl ether, toluene, cyclohexane, heptanes, 1-butanol, 2-propanol, trifluoroethanol, dimethyl carbonate, t-butyl methyl ether, isopropyl acetate, ethanol, l-methoxy-2-propanol, cyclohexanone, dimethyl formamide, 2-methoxyethyl ether, methanol:5vol%H 2 O, acetonitrile:5vol%H 2 O, acetone:5vol%H 2 O, tetrahydrofur
  • Vapor diffusions were also conducted in selected solvents.
  • the four crystallization modes used were: • temperature-cycled ripening of slurries
  • the temperature-cycle, rapid cool, and vapor diffusion samples formed a single group (Group A/Input) based on Raman and XPRD analyses. Most evaporative samples also produced Group A. However, five additional groups (Group B, Group C, Group D, Group E, and Group F) were produced from evaporative and evaporative scale-up experiments based on Raman analyses. These groups were selected for further analysis and/or scale-up.
  • Group B was an evaporative experiment from nitromethane produced in very low yields ( ⁇ 3 mg). This sample was analyzed by Raman, XPRD, and DSC. Insufficient sample was present for TG-IR (thermogravimetric-infrared spectroscopy). Six scale-up experiments were set up and each produced an amorphous or oily solid. The XPRD data did not match any of the known forms, and an unusually large low angle peak was present. The remaining seeds were used in a competitive ripening experiment in nitromethane with the input. Raman analysis after one week matched Group A (polymorph form HC14).
  • Group C was produced from two evaporative experiments from acetone and 2-butanone in very low yields ( ⁇ 1 mg). This sample was analyzed by Raman, and insufficient sample was present for further analysis. A total of fourteen scale-up experiments were set up, seven in acetone and seven in 2-butanone. The acetone experiments resulted in either Group A (polymorph form HC14) or amorphous/oily solids. Most of the 2-butanone experiments produced a new group, Group E. Since scale-up experiments for Group C were unsuccessful, the remaining seeds were used in a competitive ripening experiment in acetone with the input. Raman analysis after one week matched Group A, polymorph form HC14.
  • Group D a newly identified polymorph referred to as polymorph form HC15, was produced from a very slow evaporation experiment from acetone with 20% water in good yields ( ⁇ 20 mg). This sample was analyzed by Raman and was unstable and converted to Group E (polymorph form HC13).
  • Group E was analyzed by Raman, XPRD, DSC, and TG-IR. Loss of 6.4% water (1.0 eq) was initially seen by TG-IR, and after one week, a repeat TG experiment showed loss of 4.9% water (0.8 eq). Three attempts to reproduce the Group D/E form in acetone/water mixtures were unsuccessful and resulted in Group A (polymorph form HC14).
  • Group F was produced from several evaporative scale-up experiments in 2- butanone in very low yields ( ⁇ 0.5 mg). This sample was analyzed by Raman, XPRD, and DSC. Insufficient sample was present for TG-IR. However, closer analysis of the Raman, XPRD, and DSC data strongly suggests that Group F is a mixture of Group A (polymorph form HC14) and E (polymorph form HC13).
  • XRPD patterns were obtained using a high-throughput XRPD set-up.
  • the plates were mounted on a Bruker GADDS diffractometer equipped with a Hi-Star area detector.
  • the XRPD platform was calibrated using Silver Behenate for the long d-spacings and Corundum for the short d-spacings.
  • the carrier material used during XRPD analysis was transparent to X-rays and contributed only slightly to the background.
  • Cell constants and an orientation matrix for data collection were obtained from least-squares refinement using the setting angles of 9176 reflections in the range 7° ⁇ ⁇ 66° [CrystalClear: An Integrated Program for the Collection and Processing of Area Detector Data, Rigaku Corporation, ⁇ 1997-2002].
  • the space group was determined by the program XPREP [Bruker, XPREP in SHELXTL v. 6.12., Bruker AXS Inc., Madison, WI, USA, 2002].
  • the space group was determined to be The quality of the structure obtained was high, as indicated by the i?-value of 0.027 (2.7%). Usually R -values in the range of 0.02 to 0.06 are quoted for the most reliably determined structures [Glusker, Jenny Pickworth; Trueblood, Kenneth N. Crystal
  • Fooo 576.0 weighting l/[ ⁇ 2 ( ⁇ o 2 )+(0.0405P) 2 +0.0000P] where P ( F 0 2 +2F c 2 )/3 data collected 9176 unique data 2305
  • X-ray Powder diffraction (XRPD) of Single Crystal Samples [0153] X-ray powder diffraction (XRPD) analyses were performed on the X-ray single crystal samples described in Example 6. X-ray powder diffraction (XRPD) analyses used an Inel XRG-3000 diffractometer equipped with a CPS (Curved Position Sensitive) detector with a 26*range of 120°. Real time data were collected using Cu-Ka radiation starting at approximately 4° 2 ⁇ at a resolution of 0.03° 2 ⁇ . The tube voltage and amperage were set to 40 kV and 30 mA, respectively. The monochromator slit was set at 5 mm by 160 ⁇ m. The pattern is displayed from 2.5-40° 2 ⁇ .
  • Samples were prepared for analysis by packing them into thin- walled glass capillaries. Each capillary was mounted onto a goniometer head that is motorized to permit spinning of the capillary during data acquisition. The samples were analyzed for 300 seconds. Instrument calibration was performed using a silicon reference standard. The experimental XRPD pattern was collected at SSCI, Inc. according to cGMP specifications.
  • Figures 7 and 8 A show two different experimental XRPD pattern collected for two different preparations of the hydrochloride salt of (S)-3-aminomethyl-7-(3- hydroxy-propoxy)-3H-benzo[c] [ 1 ,2]oxaborol- 1 -ol.
  • Figure 7 is an XRPD pattern collected from a sample of polymorph form HC14 prepared according to Example 2, Method A.
  • the X-ray powder diffraction pattern shown in Figure 8 A was obtained using a sample of polymorph form HC14 prepared as described in Example 2, Method B, and was acquired using a PANalytical X'Pert Pro diffractometer. Samples were gently flattened onto a zero-background silicon insert sample holder. A continuous 2 ⁇ scan range of 2 to 40 degrees was used with a CuKa radiation source and a generator power of 40 kV and 45 mA. A 2 ⁇ step size of 0.017 degrees/step with a step time of 20.0 seconds was used. Samples were rotated at 30 rpm. Experiments were performed at room temperature and at ambient humidity.
  • Figure 8B lists peaks at degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ and d-spacing values which characterize (S)-3- aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol polymorph form HC14 as shown in Fig. 8 A.
  • the entire list of peaks, or a subset thereof, may be sufficient to characterize (S)-3-aminomethyl-7-(3-hydroxy- propoxy)-3H-benzo[c][l,2]oxaborol-l-ol polymorph form HC14.
  • Figure 9 shows a DSC thermogram for a sample of the hydrochloride salt of
  • FIG. 10 shows a TGA thermogram acquired using a TA Instruments Q500 Thermogravimetric Analyzer.
  • the sample pan was tared, and sample of (S)-3- aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol polymorph form HC14 prepared in Example 2, Method-B, was placed in the pan.
  • the temperature was ramped at a rate of 15 °C/minute.
  • a stepwise weight-loss of 6.4% was observed between 162 and 214 0 C and is associated with water-loss due to reversible chemical transformation. Further decomposition is observed beyond 214 0 C.
  • Form HClS Form HClS
  • Form HC13 exhibits characteristics consistent with a hydrated crystalline form in that it exhibits a weight loss below 100 0 C that coincides with the evolution of water.
  • Form HC13 exhibits peaks at the following wavenumbers (cm 1 ): 33049.9, 2962.2, 2941.8, 2918.2, 1583.3, 1297.9, 1247.4, 1066.5, 870.4, 686.1, 530.5, 316.2, 228.5, 161.4, 137.1.
  • the entire list of peaks, or a subset thereof, may be sufficient to characterize (S)-3-aminomethyl-7-(3-hydroxy- propoxy)-3H-benzo[c][l,2]oxaborol-l-ol polymorph form HC13.
  • X-ray powder diffraction pattern of (S)-3-aminomethyl-7-(3- hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol polymorph form HC13 prepared in Example 2 was acquired using a PANalytical X'Pert Pro diffractometer. Samples were gently flattened onto a zero-background silicon insert sample holder. A continuous 2 ⁇ scan range of 2 to 40 degrees was used with a CuKa radiation source and a generator power of 40 kV and 45 rnA. A 2 ⁇ step size of 0.017 degrees/step with a step time of 20.0 seconds was used. Samples were rotated at 30 rpm.
  • Figure 12B lists peaks at degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ , and d-spacing values (in angstroms), which characterize Form HC13 as seen in the XRPD pattern of Fig. 12A.
  • the entire list of peaks, or a subset thereof, may be sufficient to characterize (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H- benzo[c][l,2]oxaborol-l-ol polymorph form HC13.
  • DSC thermogram was acquired using a TA Instruments QlOO Differential Scanning Calorimeter.
  • the TGA thermogram of polymorph form HC13 was acquired using a TA Instruments Q500 Thermogravimetric Analyzer. The sample pan was tared, and sample of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c] [ 1 ,2]oxaborol- 1 -ol polymorph form HC13 prepared as described above was placed in the pan. The temperature was ramped at a rate of 15 °C/minute. A weight- loss of 4.7% between 27 and 104 0 C was observed and is associated with water- loss due to dehydration. Further decomposition is observed beyond 214 0 C. The TGA thermogram is shown in Fig. 14.
  • Form HC12 exhibits peaks at the following wavenumbers (cm "1 ): 3051.4, 2954.9, 2941.2, 2910.4, 1604.2, 1580.8, 1453.3, 1297.9, 1262.8, 1247.3, 1226.8, 1167.6, 1068.4, 686.7, 597.2.
  • the entire list of peaks, or a subset thereof, may be sufficient to characterize (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l- ol polymorph form HC12.
  • Figures 16A show an X-ray powder diffraction pattern of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol polymorph form HC12 prepared as described above, acquired using a PANalytical X'Pert Pro diffractometer. Samples were gently flattened onto a zero-background silicon insert sample holder. A continuous 2 ⁇ scan range of 2 to 40 degrees was used with a CuKa radiation source and a generator power of 40 kV and 45 mA. A 2 ⁇ step size of 0.017 degrees/step with a step time of 20.0 seconds was used. Samples were rotated at 30 rpm.
  • Figure 16B lists peaks at degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ and d-spacing values which characterize Form HC12 as shown in Fig. 16A.
  • the entire list of peaks, or a subset thereof, may be sufficient to characterize (S)-3- aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l-ol polymorph form HC12.
  • Figure 17 shows a DSC thermogram acquired using a TA Instruments QlOO Differential Scanning Calorimeter.
  • a sample of (S)-3-aminomethyl-7-(3-hydroxy- propoxy)-3H-benzo[c][l,2]oxaborol-l-ol polymorph form HC12 prepared as described above was accurately weighed out directly into an aluminum DSC pan.
  • the pan was sealed by applying pressure by hand and pushing each part the pan together (also known as a loose lid configuration).
  • the temperature was ramped at a rate of 15 °C/minute.
  • An endothermic transition having an onset of 49.5 0 C and an enthalpy of 31.9 J/g was measured.
  • An additional endotherm having an onset of 135.8 0 C and an enthalpy of 156.4 J/g was measured.
  • Form HC15 A sample of (S)-3-aminomethyl-7-(3-hydroxy- propoxy)-3H-benzo[c][l,2
  • Form HC15 is unstable when stored at room temperature and converts to Form HCB.
  • Form HC15 exhibits peaks at the following wavenumbers (cm 1 ): 2931.0, 2917.7, 2896.2, 1583.8, 1474.0, 1302.6, 1062.0, 685.6, 546.4, 493.3, 294.0, 262.2, 206.8, 180.9, 140.4.
  • the entire list of peaks, or a subset thereof, may be sufficient to characterize (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][l,2]oxaborol-l- ol polymorph form HC15.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne entre autres des formes polymorphiques du sel de chlorhydrate du (S)-3-aminométhyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol.
PCT/US2009/068609 2008-12-17 2009-12-17 Formes polymorphiques du (s)-3-aminométhyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2]oxaborol-1-ol WO2010080558A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP09837955A EP2378886A4 (fr) 2008-12-17 2009-12-17 Formes polymorphiques du (s)-3-aminométhyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
JP2011542458A JP2012512262A (ja) 2008-12-17 2009-12-17 （ｓ）−３−アミノメチル−７−（３−ヒドロキシ−プロポキシ）−３ｈ−ベンゾ［ｃ］［１，２］オキサボロール−１−オールの多形体
CN2009801506662A CN102256494A (zh) 2008-12-17 2009-12-17 (s)-3-氨甲基-7-(3-羟基-丙氧基)-3h-苯并[c][1,2]氧杂硼杂环戊-1-醇的多晶型物
AU2009335744A AU2009335744A1 (en) 2008-12-17 2009-12-17 Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy) -3H-benzo[c][1,2] oxaborol-1-ol
MX2011006334A MX2011006334A (es) 2008-12-17 2009-12-17 Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol.
EA201190034A EA201190034A1 (ru) 2008-12-17 2009-12-17 Полиморфы (s)-3-аминометил-7-(3-гидроксипропокси)-3н-бензо[c][1,2]оксаборол-1-ола
CA2744231A CA2744231A1 (fr) 2008-12-17 2009-12-17 Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2]oxaborol-1-ol
MA34028A MA32977B1 (fr) 2008-12-17 2009-12-17 Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
SG2011041894A SG172040A1 (en) 2008-12-17 2009-12-17 Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
BRPI0922566A BRPI0922566A2 (pt) 2008-12-17 2009-12-17 polimorfo cristalino, composição farmacêutica, composto, e, métodos para preparar um composto, e para tratar uma doença.
IL213060A IL213060A0 (en) 2008-12-17 2011-05-23 Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2]oxaborol-1-ol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13849008P 2008-12-17 2008-12-17
US61/138,490 2008-12-17

Publications (1)

Publication Number Publication Date
WO2010080558A1 true WO2010080558A1 (fr) 2010-07-15

Family

ID=42316734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/068609 WO2010080558A1 (fr) 2008-12-17 2009-12-17 Formes polymorphiques du (s)-3-aminométhyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2]oxaborol-1-ol

Country Status (18)

Country Link
US (1) US8461364B2 (fr)
EP (1) EP2378886A4 (fr)
JP (1) JP2012512262A (fr)
KR (1) KR20110111407A (fr)
CN (1) CN102256494A (fr)
AU (1) AU2009335744A1 (fr)
BR (1) BRPI0922566A2 (fr)
CA (1) CA2744231A1 (fr)
CO (1) CO6390029A2 (fr)
CR (1) CR20110357A (fr)
DO (1) DOP2011000183A (fr)
EA (1) EA201190034A1 (fr)
IL (1) IL213060A0 (fr)
MA (1) MA32977B1 (fr)
MX (1) MX2011006334A (fr)
PE (1) PE20120052A1 (fr)
SG (1) SG172040A1 (fr)
WO (1) WO2010080558A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013093615A1 (fr) 2011-12-22 2013-06-27 Micurx Pharmaceuticals, Inc. Composés de bore tricycliques pour une thérapie antimicrobienne
WO2015021396A2 (fr) 2013-08-09 2015-02-12 Glaxosmithkline Intellectual Property (No.2) Limited Composés de benzoxaborole tricyclique et leurs utilisations
US9138002B2 (en) 2013-01-30 2015-09-22 Agrofresh Inc. Compounds and compositions
WO2016001834A1 (fr) 2014-07-01 2016-01-07 Daiichi Sankyo Company, Limited Benzoxaboroles tricycliques en tant qu'agents antibactériens
WO2016128949A1 (fr) 2015-02-12 2016-08-18 Glaxosmithkline Intellectual Property (No.2) Limited Composés benzoxaborole et leurs utilisations
US9426996B2 (en) 2013-01-30 2016-08-30 Agrofresh Inc. Use of benzoxaboroles as volatile antimicrobial agents on meats, plants, or plant parts
JP2016199558A (ja) * 2010-09-07 2016-12-01 アナコール ファーマシューティカルズ，インコーポレーテッド 細菌感染治療用のベンゾオキサボロール誘導体
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US10961261B2 (en) 2017-03-01 2021-03-30 Anacor Pharmaceuticals, Inc. Oxaborole analogs and uses thereof
US10966429B2 (en) 2016-03-07 2021-04-06 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
JP2021073212A (ja) * 2010-08-10 2021-05-13 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
WO2022043936A1 (fr) 2020-08-31 2022-03-03 Pfizer Inc. Procédés de protection de l'arn

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008131324A (ru) 2005-12-30 2010-02-10 Анакор Фармасьютикалз, Инк. (Us) Борсодержащие малые молекулы
CA2933994A1 (fr) 2006-02-16 2007-08-23 Anacor Pharmaceuticals, Inc. Petites molecules contenant du bore en tant qu'agents anti-inflammatoires
WO2011094450A1 (fr) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Petites molecules contenant du bore
WO2014121124A1 (fr) 2013-02-01 2014-08-07 Anacor Pharmaceuticals, Inc. Molécules de petite taille contenant du bore en qualité d'agents anti-protozoaires

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591731A (en) * 1992-07-31 1997-01-07 U.S. Bioscience, Inc. Crystalline amifostine compositions
US5880188A (en) * 1994-06-09 1999-03-09 Zeneca Limited Oxaboroles and salts thereof, and their use as biocides
US20070293457A1 (en) * 2006-02-16 2007-12-20 Baker Stephen J Boron-containing small molecules as anti-inflammatory agents

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2260336A (en) 1939-10-16 1941-10-28 Dow Chemical Co Method of preparation of organic borates
GB1396904A (en) 1972-08-11 1975-06-11 Ici Ltd Method for the control of micro-organisms
US4766113A (en) 1975-10-24 1988-08-23 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4602011A (en) 1975-10-24 1986-07-22 Chapman Chemical Company Antimicrobial compositions and methods of using same
US4716035A (en) 1985-05-24 1987-12-29 The Procter & Gamble Company Oral compositions and methods for treating gingivitis
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4894220A (en) 1987-01-30 1990-01-16 Colgate-Palmolive Company Antibacterial antiplaque oral composition
US5348948A (en) 1993-05-07 1994-09-20 American Cyanamid Company 2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal
US5348947A (en) 1993-05-07 1994-09-20 American Cyanamid Company Diarylboron ester and thioester fungicidal agents
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
US5831046A (en) 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
US6413751B1 (en) 1996-09-19 2002-07-02 The Board Of Trustees Of The Leland Stanford Jr. University DNA adenine methyltransferases and uses thereof
DE19829947A1 (de) 1998-07-04 2000-01-05 Bayer Ag Elektrolumineszierende Anordnungen mit Bor-Chelaten
WO2000044387A1 (fr) 1999-01-29 2000-08-03 Nitto Kasei Co., Ltd. Composes organobores presentant une activite de coccidiostats
EP1181291A2 (fr) 1999-05-25 2002-02-27 The Penn State Research Foundation Inhibiteurs de methyltransferase d'adn
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
WO2001025226A1 (fr) 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Derives de dithiolane
AU7593001A (en) 2000-07-14 2002-01-30 Zycos Inc Alpha-msh related compounds and methods of use
JP2004524281A (ja) 2000-11-30 2004-08-12 ザ ペン ステート リサーチ ファウンデイション Ｄｎａメチルトランスフェラーゼ阻害剤
DE10110051C2 (de) 2001-03-02 2003-07-03 Clariant Gmbh Verfahren zur Herstellung von Boron- und Borinsäuren
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10143979A1 (de) 2001-09-07 2003-03-27 Clariant Gmbh Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
US7217701B2 (en) 2001-10-11 2007-05-15 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
US7405304B2 (en) 2002-01-10 2008-07-29 The Penn State Research Foundation Methods for the preparation of alkyl diaryl borinates and complexed diarylboronic acids
JP2006511613A (ja) 2002-12-18 2006-04-06 アナコア ファーマシューティカルズ インコーポレイテッド ボロン酸複合体を含む抗生物質および使用法
US7390806B2 (en) 2002-12-18 2008-06-24 Anacor Pharmaceuticals, Inc. Antibiotics containing borinic acid complexes and methods of use
WO2005000200A2 (fr) 2003-05-09 2005-01-06 Sugen, Inc. Nouvelles kinases
MXPA05013848A (es) 2003-06-16 2006-09-04 Anacor Pharmaceuticals Inc Agentes terapeuticos que contienen boro hidroliticamente resistentes y metodos de uso.
JP5905183B2 (ja) 2004-05-12 2016-04-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 感染を処置するためのゲルソリンの使用
WO2006062731A1 (fr) 2004-11-19 2006-06-15 University Of North Texas Health Science Center At Fort Worth Utilisation de la phenanthroline et de ses derives pour abaisser la tension intraoculaire d'un oeil affecte
GB0501944D0 (en) 2005-01-31 2005-03-09 Univ Cambridge Tech Compounds for use in chemical detection and/or quantitation
DK2343304T3 (en) 2005-02-16 2015-06-29 Anacor Pharmaceuticals Inc BIOCIDE BORONOPHTHALIDE COMPOUNDS
US20060229347A1 (en) 2005-03-30 2006-10-12 Astion Development A/S Treatment of eczemas
US20080234229A1 (en) 2005-08-18 2008-09-25 Auspex Pharmaceuticals, Inc. Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders
RU2008131324A (ru) 2005-12-30 2010-02-10 Анакор Фармасьютикалз, Инк. (Us) Борсодержащие малые молекулы
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
WO2007146965A2 (fr) 2006-06-12 2007-12-21 Anacor Pharmaceuticals, Inc. Composés destinés au traitement d'une maladie périodontale
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
KR100895300B1 (ko) 2007-07-20 2009-05-07 한국전자통신연구원 생체신호 측정의복과 생체신호 처리시스템
EP2187893A4 (fr) 2008-03-06 2012-02-22 Anacor Pharmaceuticals Inc Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires
WO2009140309A2 (fr) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
WO2010028005A1 (fr) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
WO2010045505A1 (fr) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Petites molécules contenant du bore en tant qu’agents antiprotozoaires
US9493489B2 (en) 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591731A (en) * 1992-07-31 1997-01-07 U.S. Bioscience, Inc. Crystalline amifostine compositions
US5880188A (en) * 1994-06-09 1999-03-09 Zeneca Limited Oxaboroles and salts thereof, and their use as biocides
US20070293457A1 (en) * 2006-02-16 2007-12-20 Baker Stephen J Boron-containing small molecules as anti-inflammatory agents

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11684629B2 (en) 2010-08-10 2023-06-27 Melinta Subsidiary Corp. Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
JP7227282B2 (ja) 2010-08-10 2023-02-21 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
JP2021073212A (ja) * 2010-08-10 2021-05-13 レンペックス・ファーマシューティカルズ・インコーポレイテッド 環状ボロン酸エステル誘導体およびその治療的使用
US9751898B2 (en) 2010-09-07 2017-09-05 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US11008345B2 (en) 2010-09-07 2021-05-18 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP2019112431A (ja) * 2010-09-07 2019-07-11 アナコール ファーマシューティカルズ，インコーポレーテッド 細菌感染治療用のベンゾオキサボロール誘導体
JP2016199558A (ja) * 2010-09-07 2016-12-01 アナコール ファーマシューティカルズ，インコーポレーテッド 細菌感染治療用のベンゾオキサボロール誘導体
JP2018058836A (ja) * 2010-09-07 2018-04-12 アナコール ファーマシューティカルズ，インコーポレーテッド 細菌感染治療用のベンゾオキサボロール誘導体
US8530452B2 (en) 2011-12-22 2013-09-10 Micurx Pharmaceuticals, Inc. Tricyclic boron compounds for antimicrobial therapy
WO2013093615A1 (fr) 2011-12-22 2013-06-27 Micurx Pharmaceuticals, Inc. Composés de bore tricycliques pour une thérapie antimicrobienne
US10765117B2 (en) 2013-01-30 2020-09-08 Agrofresh Inc. Volatile applications against pathogens
US9138002B2 (en) 2013-01-30 2015-09-22 Agrofresh Inc. Compounds and compositions
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US9426996B2 (en) 2013-01-30 2016-08-30 Agrofresh Inc. Use of benzoxaboroles as volatile antimicrobial agents on meats, plants, or plant parts
US11917997B2 (en) 2013-01-30 2024-03-05 Agrofresh Inc. Volatile applications against pathogens
US11771089B2 (en) 2013-01-30 2023-10-03 Agrofresh Inc. Large-scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US11202448B2 (en) 2013-01-30 2021-12-21 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
EP4029870A1 (fr) 2013-08-09 2022-07-20 GlaxoSmithKline Intellectual Property (No.2) Limited Composés de benzoxaborole tricyclique et leurs utilisations
WO2015021396A2 (fr) 2013-08-09 2015-02-12 Glaxosmithkline Intellectual Property (No.2) Limited Composés de benzoxaborole tricyclique et leurs utilisations
WO2016001834A1 (fr) 2014-07-01 2016-01-07 Daiichi Sankyo Company, Limited Benzoxaboroles tricycliques en tant qu'agents antibactériens
WO2016128949A1 (fr) 2015-02-12 2016-08-18 Glaxosmithkline Intellectual Property (No.2) Limited Composés benzoxaborole et leurs utilisations
WO2016128948A1 (fr) 2015-02-12 2016-08-18 Glaxosmithkline Intellectual Property (No.2) Limited Composés benzoxaborole substitués en position 4 et utilisations associées
US10966429B2 (en) 2016-03-07 2021-04-06 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
US11691992B2 (en) 2017-03-01 2023-07-04 Anacor Pharmaceuticals, Inc. Oxaborole analogs and uses thereof
US10961261B2 (en) 2017-03-01 2021-03-30 Anacor Pharmaceuticals, Inc. Oxaborole analogs and uses thereof
WO2022043936A1 (fr) 2020-08-31 2022-03-03 Pfizer Inc. Procédés de protection de l'arn

Also Published As

Publication number Publication date
CA2744231A1 (fr) 2010-07-15
AU2009335744A1 (en) 2010-07-15
IL213060A0 (en) 2011-07-31
PE20120052A1 (es) 2012-02-13
CN102256494A (zh) 2011-11-23
US8461364B2 (en) 2013-06-11
CR20110357A (es) 2011-11-11
BRPI0922566A2 (pt) 2017-03-28
EA201190034A1 (ru) 2012-02-28
DOP2011000183A (es) 2011-07-15
SG172040A1 (en) 2011-07-28
CO6390029A2 (es) 2012-02-29
MA32977B1 (fr) 2012-01-02
US20110152217A1 (en) 2011-06-23
JP2012512262A (ja) 2012-05-31
KR20110111407A (ko) 2011-10-11
MX2011006334A (es) 2011-09-22
EP2378886A1 (fr) 2011-10-26
EP2378886A4 (fr) 2012-08-29

Similar Documents

Publication Publication Date Title
US8461364B2 (en) Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[C][1,2]oxaborol-1-OL
CN114728899B (zh) 新型三苯基化合物盐
EP3686199B9 (fr) Dérivé à cycle fusionné utilisé en tant qu'inhibiteur du récepteur a2a
EP4327880A2 (fr) Forme à l'état solide de succinate de ribociclib
EP2793901A1 (fr) Composés de bore tricycliques pour une thérapie antimicrobienne
CN110225904A (zh) 制备细胞毒性苯二氮卓衍生物的方法
WO2018196812A1 (fr) Composé d'ester de borate et d'acide borique, son procédé de préparation et son utilisation
WO2018041260A1 (fr) Inhibiteur de protéine de reconnaissance de bromodomaine, son procédé de préparation et son utilisation
WO2016011195A1 (fr) Formes solides de th-302 et procédés associés
KR20120053027A (ko) 페소테로딘 푸마레이트 및 페소테로딘 염기의 결정형
TW202208325A (zh) （Ｒ）—羥布托尼（Ｏｘｙｂｕｔｙｎｉｎ）鹽酸鹽之多晶形式
EP2078014A2 (fr) Formes cristallines et amorphes de tiagabine
BR112021001963A2 (pt) borato de derivado de azetidina
TWI717859B (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
US20240239791A1 (en) Processes for the synthesis of valbenazine
WO2023061372A1 (fr) Sel de malate de dérivé de xanoméline, forme cristalline a, procédé de préparation correspondant et utilisation associée
WO2023143321A1 (fr) Forme cristalline de tavapadon, son procédé de préparation et son utilisation
CN111718340A (zh) 氘代Palbociclib化合物的晶型、制备方法及应用
TW202328152A (zh) 氮雜內醯胺化合物之晶型
Mabkhot et al. SPONTANEOUS α‐METHYLATION OF AN α-BROMOKETONE FROM DMF: SYNTHESIS AND CRYSTALLINE STRUCTURE OF 1, 1'-(3, 4-DIPHENYLTHIENO [2, 3-b] THIOPHENE-2, 5-DIYL) BIS (PROPAN-1-ONE)
TW202404973A (zh) Ｎ—甲基—Ｎ—（（１Ｓ，３Ｓ）—３—甲基—３—（（６—（１—甲基—１Ｈ—吡唑—４—基）吡唑并［１，５—ａ］吡嗪—４—基）氧基）環丁基）丙烯醯胺之結晶多形體
JP5442198B2 (ja) 医薬化合物の結晶形
CN117836285A (zh) Aurora a选择性抑制剂的多晶型及其用途
CN117480170A (zh) 用于合成缬苯那嗪的方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980150666.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09837955

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2744231

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 213060

Country of ref document: IL

Ref document number: 2126/KOLNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009335744

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 593099

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 11071901

Country of ref document: CO

Ref document number: 201190034

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/006334

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2011542458

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009335744

Country of ref document: AU

Date of ref document: 20091217

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011001479

Country of ref document: CL

Ref document number: 12011501234

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 001246-2011

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: CR2011-000357

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: DZP2011000462

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2009837955

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20117016565

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: a201106343

Country of ref document: UA

ENP Entry into the national phase

Ref document number: PI0922566

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110616